Logo Logo
Help
Contact
Switch Language to German
Alig, Stefan; Jurinovic, Vindi; Pastore, Alessandro; Haebe, Sarah; Schmidt, Christian; Zoellner, Anna-Katharina; Dreyling, Martin; Unterhalt, Michael; Hoster, Eva; Hiddemann, Wolfgang; Weigert, Oliver (2019): Impact of age on clinical risk scores in follicular lymphoma. In: Blood Advances, Vol. 3, No. 7: pp. 1033-1038
Full text not available from 'Open Access LMU'.

Abstract

The Follicular Lymphoma (FL) International Prognostic Index (FLIPI) and FLIPI-2 are well-described clinical risk models. Age \textgreater60 years at diagnosis is a risk factor in both scores. Recently, we showed that older age is not associated with higher risk of disease progression or inferior treatment efficacy. Instead, shorter survival of older patients results mainly from an increased risk of nonrelapse deaths. This questions the value of age as a meaningful component of scores intended to predict disease-specific survival. The newly proposed PRIMA-prognostic index (PRIMA-PI) only includes \textgreekb2-microglobulin levels and bone marrow infiltration as risk factors. Here, we independently validate the PRIMA-PI in a clinical trial cohort of 475 patients with advanced FL who uniformly received cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, and rituximab (R-CHOP) as frontline therapy. The PRIMA-PI separated 3 similar sized risk cohorts with 5-year progression-free survival (PFS) rates of 74%, 59%, and 39%, respectively (P \textless .0001). Furthermore, we compare the PRIMA-PI with the FLIPI and FLIPI-2. We demonstrate that the PRIMA-PI has the highest specificity to identify high-risk patients (80% for 5-year PFS) because of its superior risk stratification in patients \textgreater60 years (73% vs 33% FLIPI and 47{\%} FLIPI-2 for 5-year PFS). Thus, the PRIMA-PI is a promising clinical tool to stringently identify patients at highest risk of poor outcome after frontline R-CHOP for advanced FL, and is particularly useful in patients with older age. Further validation in non-R-CHOP treated cohorts is needed.